Angiogenesis
Angiogenesis(血管生成)
Angiogenesis 相关产品(355)
- GC38329GB-110 hydrochloride纯度: >99.50%
GB-110 hydrochloride 是一种有效的，具有口服活性的，非肽类的 protease activated receptor 2 (PAR2) 激动剂。GB-110 hydrochloride 选择性诱导 PAR2 介导的 HT29 细胞内 Ca2+ 释放，EC50 值为 0.28 μM。
- GC38375RemibrutinibCAS: 1787294-07-8纯度: >99.00%
Remibrutinib (LOU064) is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases.
- GC387312-Furoyl-LIGRLO-amide TFACAS: 2468029-34-5
2-Furoyl-LIGRLO-amide TFA 是一种有效的选择性蛋白酶激活受体2 (PAR2) 激动剂， 其 pD2 值为 7.0。
- GC38767DeoxyshikoninCAS: 43043-74-9纯度: >99.50%
Deoxyshikonin是从紫草（ Lithospermum erythrorhizon Sieb ）中分离得到的一种具有抗肿瘤活性的天然产物。
- GC38873α2β1 Integrin Ligand Peptide TFA纯度: >99.00%
α2β1 Integrin Ligand Peptide TFA 在细胞膜表面与 α2β1 整合素受体相互作用,进入细胞介导细胞外信号。α2β1 Integrin Ligand Peptide是一种潜在的胶原受体拮抗剂。
- GC38893BMS-688521CAS: 893397-44-9纯度: >99.50%
BMS-688521 是一种高效、具有口服活性的 LFA-1/ICAM 相互作用抑制剂，在粘附试验中 IC50 为 2.5 nM，在 MLR 试验中 IC50 为 60 nM。BMS-688521 对小鼠变应性嗜酸性肺炎模型有较好的治疗作用。
- GC39194Ibrutinib D5CAS: 1553977-17-5纯度: >98.00%
An internal standard for the quantification of ibrutinib
- GC40085Pazopanib-d6CAS: 1219592-01-4纯度: >99.00%
An internal standard for the quantification of pazopanib
- GC40213Regorafenib-13C-d3CAS: 2126178-55-8纯度: >99.00%
An internal standard for the quantification of regorafenib
- GC40466(±)11(12)-EETCAS: 87173-81-7纯度: >95.00%
A racemic version of a CYP450 metabolite of arachidonic acid
- GC41655(±)19(20)-EDP EthanolamideCAS: 2123485-34-5纯度: >98.00%
An ω-3 endocannabinoid epoxide and CB receptor agonist
- GC424094-hydroxy Nebivolol (hydrochloride)CAS: 2717115-85-8纯度: >98.00%
A major metabolite of nebivolol
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC38329 | GB-110 hydrochloride | - | >99.50% | |
GB-110 hydrochloride 是一种有效的，具有口服活性的，非肽类的 protease activated receptor 2 (PAR2) 激动剂。GB-110 hydrochloride 选择性诱导 PAR2 介导的 HT29 细胞内 Ca2+ 释放，EC50 值为 0.28 μM。 | ||||
| GC38375 | Remibrutinib | 1787294-07-8 | >99.00% | |
Remibrutinib (LOU064) is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases. | ||||
| GC38731 | 2-Furoyl-LIGRLO-amide TFA | 2468029-34-5 | - | |
2-Furoyl-LIGRLO-amide TFA 是一种有效的选择性蛋白酶激活受体2 (PAR2) 激动剂， 其 pD2 值为 7.0。 | ||||
| GC38767 | Deoxyshikonin | 43043-74-9 | >99.50% | |
Deoxyshikonin是从紫草（ Lithospermum erythrorhizon Sieb ）中分离得到的一种具有抗肿瘤活性的天然产物。 | ||||
| GC38801 | Irigenin | 548-76-5 | >98.50% | |
An isoflavonoid with diverse biological activities | ||||
| GC38873 | α2β1 Integrin Ligand Peptide TFA | - | >99.00% | |
α2β1 Integrin Ligand Peptide TFA 在细胞膜表面与 α2β1 整合素受体相互作用,进入细胞介导细胞外信号。α2β1 Integrin Ligand Peptide是一种潜在的胶原受体拮抗剂。 | ||||
| GC38893 | BMS-688521 | 893397-44-9 | >99.50% | |
BMS-688521 是一种高效、具有口服活性的 LFA-1/ICAM 相互作用抑制剂，在粘附试验中 IC50 为 2.5 nM，在 MLR 试验中 IC50 为 60 nM。BMS-688521 对小鼠变应性嗜酸性肺炎模型有较好的治疗作用。 | ||||
| GC39146 | HIF-1 inhibitor-1 | 2380261-53-8 | - | |
An inhibitor of HIF-1 signaling | ||||
| GC39194 | Ibrutinib D5 | 1553977-17-5 | >98.00% | |
An internal standard for the quantification of ibrutinib | ||||
| GC40085 | Pazopanib-d6 | 1219592-01-4 | >99.00% | |
An internal standard for the quantification of pazopanib | ||||
| GC40213 | Regorafenib-13C-d3 | 2126178-55-8 | >99.00% | |
An internal standard for the quantification of regorafenib | ||||
| GC40466 | (±)11(12)-EET | 87173-81-7 | >95.00% | |
A racemic version of a CYP450 metabolite of arachidonic acid | ||||
| GC40865 | LYG-202 | 1175077-25-4 | >98.00% | |
LYG-202是一种具有哌嗪取代基的合成黄酮类化合物，展现出显著的抗肿瘤活性。 | ||||
| GC40963 | Spirolaxine | 126382-01-2 | >95.00% | |
A phthalide antibacterial agent | ||||
| GC41191 | (±)13(14)-EpDPA | 895127-64-7 | >95.00% | |
A DHA epoxygenase metabolite | ||||
| GC41203 | (±)7(8)-EpDPA | 895127-66-9 | >95.00% | |
A DHA epoxygenase metabolite | ||||
| GC41212 | (±)10(11)-EpDPA | 895127-65-8 | >95.00% | |
A DHA epoxygenase metabolite | ||||
| GC41625 | Oroxylin A | 480-11-5 | >98.00% | |
A flavonoid with diverse biological activities | ||||
| GC41648 | (±)13(14)-DiHDPA | 1345275-24-2 | >98.00% | |
A metabolite of DHA | ||||
| GC41653 | (±)16(17)-DiHDPA | 1345275-27-5 | >95.00% | |
An epoxygenase metabolite of DHA | ||||
| GC41655 | (±)19(20)-EDP Ethanolamide | 2123485-34-5 | >98.00% | |
An ω-3 endocannabinoid epoxide and CB receptor agonist | ||||
| GC42409 | 4-hydroxy Nebivolol (hydrochloride) | 2717115-85-8 | >98.00% | |
A major metabolite of nebivolol | ||||
| GC42887 | Axitinib Sulfoxide | 1347304-18-0 | >98.00% | |
A major inactive metabolite of axitinib | ||||
| GC43198 | CAY10717 | 1240322-54-6 | >95.00% | |
A multi-targeted kinase inhibitor | ||||